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ABSTRACT
Gastrointestinal (GI) diseases, and in particular those caused by bacterial infections, are a major cause of 
morbidity and mortality worldwide. Treatment is becoming increasingly difficult due to the increase in 
number of species that have developed resistance to antibiotics. Probiotic lactic acid bacteria (LAB) have 
considerable potential as alternatives to antibiotics, both in prophylactic and therapeutic applications. 
Several studies have documented a reduction, or prevention, of GI diseases by probiotic bacteria. Since 
the activities of probiotic bacteria are closely linked with conditions in the host’s GI-tract (GIT) and 
changes in the population of enteric microorganisms, a deeper understanding of gut-microbial inter-
actions is required in the selection of the most suitable probiotic. This necessitates a deeper under-
standing of the molecular capabilities of probiotic bacteria. In this review, we explore how probiotic 
microorganisms interact with enteric pathogens in the GIT. The significance of probiotic colonization 
and persistence in the GIT is also addressed.
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Lactic acid bacteria (LAB) play a major role in the 
preservation and organoleptic profile of fermented 
food products, but are equally important in affecting 
the composition and diversity of intestinal 
microbiota.1–3 Some of the most important beneficial 
effects include stimulation of the host’s immune system, 
prevention of antibiotic-associated diarrhea, treatment 
of inflammatory bowel disease (IBD) and irritable bowel 
syndrome (IBS), alleviation of lactose intolerance, low-
ering of cholesterol levels and prevention of life- 
threatening GI infections such as Clostridium difficile- 
associated diarrhea.4–8 Renewed interest in probiotics 
initiated the launch of an increasing number of probio-
tic-containing supplements that claim to confer specific 
health benefits to the consumer.9,10 Many of these pro-
ducts are driven by aggressive marketing through phar-
maceutical and nutritional companies, often without 
a clear understanding of the interactions between pro-
biotic bacteria, normal commensal microorganisms, 
pathogens and the host.
Lactic acid bacteria are indigenous to the small and 
large intestine of humans and animals and exert 
a number of probiotic properties, such as binding to 
receptors and physically excluding pathogens, pro-
duction of antimicrobial substances, strengthening 
of the gut mucosal barrier and modulation of the 
immune system.11–15 It is therefore important to 
have an in-depth understanding of the specific meta-
bolic and genetic interactions between probiotic bac-
teria, the host intestinal mucosa and enteric 
pathogens in the GIT. Commensal bacteria also act 
as a protective barrier against pathogens by providing 
mucosal protection and stimulation of the immune 
system.10,15 The most predominant genera used in 
probiotic supplements are Lactococcus, Lactobacillus 
and Bifidobacterium spp. derived from humans and 
animals.11 It is important that probiotic strains survive 
passage through the stomach, resist bile salts and 
digestive enzymes in the small intestinal tract and 
reach the colon in sufficient numbers.16 The number 
of viable cells surviving the journey through the GIT 
is, however, strain specific and depends on the dosage 
and duration of administration.10,16
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Due to the complex nature of the human 
GIT, only a few in-depth studies on interactions 
between probiotic bacteria and enteric patho-
gens have been published and many rely on 
in vitro data to decipher the mechanistic basis 
underlying a specific health benefit.17 A specific 
health benefit may also be attributed to 
a combination of mechanisms. This is impor-
tant, as strains from the same species may 
evoke different responses in the host.13 Several 
probiotic strains secrete secondary metabolites 
and peptides with antimicrobial activity that 
may interact directly with the host or 
pathogens.15,18 Ultimately, a detailed character-
ization of these interactions will significantly 
improve the application of probiotics to sup-
port and enhance human health. In this review, 
the mechanisms probiotic bacteria use to inter-
act with enteric pathogens, and the ability to 
colonize the GIT, are discussed.
Colonization and persistence of probiotic 
bacteria in the GIT
Strains that colonize the GIT have a greater bene-
ficial effect on the host than strains passing through 
the GIT.
19–21 This may be because adhesion to 
mucus and epithelial cells not only provides the 
strain with a competitive advantage, but forms 
a stronger interaction with the host that leads to 
recognition of the probiotic and stimulation of the 
host’s immune response.15,17 Furthermore, coloni-
zation by probiotic strains prevents adhesion of 
enteric pathogens to intestinal cells.22 Several stu-
dies have shown how probiotics interfere with the 
ability of GI pathogens, such as Salmonella typhi-
murium, Clostridium sporogenes and Enterococcus 
faecalis, to adhere to Caco-2 cells.23–25 A diverse 
spectrum of pathogens targeted by probiotic bac-
teria and their reported health promoting effects is 
listed in Table 1.
Table 1. Health effects of probiotic bacteria and main pathogens targeted.
Probiotic strains Pathogen(s)a Reported effects




Reduced diarrhea and nausea in a human trial. Immune enhancement. Used for alleviation of 
atopic dermatitis in children, stabilization of intestinal permeability
L. johnsonii La1 28 H. pylori Regular ingestion modulated H. pylori colonization in children
L. casei DG 29 H. pylori Increased eradication rate of H. pylori infection when supplemented with first-line therapies
L. casei CRL431 30 Salmonella enterica serovar 
Typhimurium
Preventative administration protected mice against infection
L. rhamnosus HN001 31 Salmonella enterica serovar 
Typhimurium
Conferred immune enhancement and protection against Salmonella infection in mice
Bifidobacterium longum Bb46 32 Salmonella enterica serovar 
Typhimurium
Protective effect against Salmonella challenge in gnotobiotic mice
L. plantarum 423 and 
Enterococcus mundtii ST4SA 33
Salmonella enterica serovar 
Typhimurium
Alleviated symptoms of Salmonella infections in challenge study using rats
L. casei BL23 and L. paracasei 
CNCM I-3689 34
Listeria monocytogenes Decreased pathogen systemic dissemination in orally infected mice
L. salivarus UC118 35 L. monocytogenes Protected mice from pathogenic infection in liver and spleen
L. plantarum 423 and E. mundtii 
ST4SA 36,37
L. monocytogenes Excluded the pathogen from the intestinal tract of mice after daily administrations of 
probiotic strains
Lactococcus lactis MM19 and 
Pediocin acidilactici MM33 38
Vancomycin resistant 
enterococci (VRE)
Modulated intestinal microbiota and reduced pathogen intestinal colonization in mice.
L. rhamnosus R0011 and 
L. acidophilus R0052 39
Citrobacter rodentium Pre-treatment with the probiotic strains attenuated pathogen infection in mice
L. reuteri 40 C. rodentium Attenuated C. rodentium-induced colitis in mice. Significantly decreased diarrhea symptoms 
in infants and children.
B. breve 41 Escherichia coli O157:H7 Protected mice from Shiga toxic-producing E. coli.
Pediococcus pentasaceus NB-17 
42
n/a Effectively stimulated immune cell activities and allergic inhibitory effects
Oenococcus oeni 9115 43 n/a Significantly decreased acid-induced colitis in mice. Modulated the immune response of 
immunocompetent cells in vitro.
B. infantis UCC 36524 4,10,42,43 Clostridium Reduced clostridia levels and increased lactobacilli and bifidobacteria. Increased blood 
phagocytic activity. Reduced inflammation in mice.
Saccharomyces boulardii 44,45 C. difficile Used for prevention and treatment of antibiotics associated and acute diarrhea in children, 
treatment of C. difficile colitis, prevention of diarrhea in critically ill tube-fed patients
B. adolescentis 46 Bacteroides 
thetaiotaomicron
Significantly modulated both systemic and intestinal immune response in germ-free rats.
L. acidophilus 47 n/a Reduced the severity of Irritable Bowel Syndrome.
aPathogen (s): n/a, not applicable
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Earlier studies on the colonization of probiotics 
were based on in vitro studies demonstrating the 
ability of strains to adhere to cell lines such as Caco- 
2, HT-29 and HT29-MTX.48,49 Although these stu-
dies simulated GIT-models and have provided 
valuable insights into the adherence of probiotic 
cells, it remains an in vitro approach that is unable 
to recapitulate the complex multicellular nature of 
the GIT. Studies using cell lines require specialized 
equipment and facilities to keep the cells viable. 
Because of these reasons, studies on the survival 
and colonization of probiotic bacteria are mostly 
done by analyzing fecal samples.50 From the recov-
ery of cells in feces after probiotic intervention, the 
persistence of strains is calculated, providing that 
cell numbers in the dosage are known and all 
methods are standardized. Probiotic cells that per-
sist in feces for the longest time and highest num-
bers indicate a higher colonization and persistence 
in the GIT. In vivo pharmacokinetics of probiotics 
can be studied by comparing cell numbers (in fecal 
material) between specific strains before and after 
ingestion.51,52 Other techniques used include 
intestinal intubation and pyxigraphy.52 Antibiotic 
resistance markers can be used to clearly identify 
probiotic cells in fecal samples.36,52 When no strain 
identification is used, results may be difficult to 
interpret, since endogenous probiotic cells can 
also be excreted in feces. The pharmacokinetics of 
different probiotic LAB using fecal recuperation are 
listed in Table 2. The survival and persistence of 
ingested probiotics differs greatly between genera 
and even between strains. Lactobacillus and 
Bifidobacterium spp. have been extensively 
explored as probiotics, since they form an integral 
part of the natural gut microbiome of humans and 
animals.11,64 Bifidobacterium lactis LAFTI B94, 
B. longum SB T2928, Lactobacillus rhamnosus 
DR20, Lactobacillus gasseri SBT2055 and 
Enterococcus mundtii ST4SA persisted in high 
numbers for the longest time Table 2. In compar-
ison, fecal recuperation of Lactococcus lactis MG 
1363 and Lactobacillus fermentum KLD was much 
lower. In a recent study, the probiotic strains 
Lactobacillus plantarum 423 and E. mundtii 
ST4SA were transformed with a plasmid containing 
the bioluminescence firefly luciferase gene (ffluc) 
from Photinus pyralis.59 This allowed monitoring 
of the migration of the strains through the GIT and 
in mouse feces in real time and in a noninvasive 
manner. With the use of bioluminescent imaging 
(BLI), the authors detected cell numbers as low as 
104 CFU/100 mg feces. Imaging revealed that 
E. mundtii ST4SA persisted in feces throughout 
the trial period (>20 days), whilst L. plantarum 
423 persisted for 13 days after the last day (day 5) 
of intragastric administration.59 BLI provides 
three-dimensional images of cells as they migrate 
through the GIT (65). Information is gathered in 
real-time, using an in vivo imaging system (IVIS). 
Only metabolically active cells are detected. The 
technique has been used in several 
studies.36,37,59,65,66 Van Zyl et al.59 used BLI to 
study the transit of L. plantarum 423 and 
E. mundtii ST4SA in the digestive tract of mice 
for 9 consecutive days. Data generated using the 
technique correlated with viable cell counts. For 
a review on the application of optical imaging sys-
tems in in vivo tracking of LAB, the reader is 
referred to ref. 66.
Some reports have suggested that non-viable and 
non-colonizing probiotics may also confer certain 
health benefits to the host.11,18,67–69 During GI pas-
sage, non-colonizing, or transiently colonizing pro-
biotic bacteria continue to be metabolically active, 
thus conferring beneficial health effects to their 
host.16 In a study by Kullen et al.70 human 







B. lactis LAFTI B94 53 1 x 1011 CFU for 
7 days
1.8 x 109 CFU/g 28
B. lactis Bb12 54 1 x 1011 CFU 8 x 107 CFU/g 14
B. longum SB T2928 
55
7 x 1011 CFU for 
7 days
1 x 109 CFU/g >30
L. rhamnosus GG 56 6 x 1010 CFU for 
12 days
4 x 104 CFU/g 14
L. rhamnosus DR20 
57
1.6 x 109 CFU for 
±182 days
6.3 x 105 CFU/g 60
L. salivarus UCC118 
58
1 x 1010 CFU for 
21 days
1 x 103–1 × 107 
CFU/g
>21
L. plantarum 423 59 4 x 109 CFU for 
5 days
1 x 105 CFU/g 18 days
L. plantarum 299 v 60 2 x 1010 CFU for 
21 days
1 x 107 CFU/g >8
L. plantarum NCIMB 
8826 51
5 x 1010 CFU for 
7 days
1 x 108 CFU/g 14
L. fermentum KLD 51 1.5 x 109 CFU 3.2 x 104 CFU/g 1
L. gasseri SBT2055 61 1 x 1011 CFU for 
7 days
1 x 107 CFU/g >31
Enterococcus mundtii 
ST4SA 59
4 x 109 CFU for 
5 days
1 x 106 CFU/ 
100 mg
>20
S. thermophilus 62 1.2 x 1012 CFU 5 x 106 CFU/g 6
Lc. lactis MG 1363 63 1 x 1011 CFU for 
4 days
1 x 104 CFU/g 3
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volunteers were administered a probiotic strain of 
Bifidobacterium and the recovery of the strain in 
feces was monitored. The strain was detected in 
feces at increasing cell numbers during days 
(8 days) of administration, but could not be recov-
ered in fecal material after the last oral administra-
tion. The authors concluded that although the 
administered strain did not colonize the human 
GIT, colonization and prolonged persistence may 
not be required to achieve a significant probiotic 
effect. Similar results were reported by Fujiwara 
and coworkers.71,72 The authors found that bifido-
bacteria produce a 100 kDa protein, which actively 
prevents the adherence of pathogenic Escherichia 
coli to intestinal mucosal cells by blocking their 
binding to the glycolipid binding receptor gang-
liotetraosylceramide. Therefore, the competitive 
exclusion of the pathogenic strain may not have 
been related to direct live cell-to-cell competition 
for intestinal adhesion sites.
Microorganisms found in fecal samples are 
usually inhabitants of the lower intestine, such as 
the colon.10 In humans, intubation at specific 
intestinal sites is used to determine probiotic colo-
nization in the upper sections of the GIT. Biopsies 
can be taken of the portions of the intestinal tract 
where probiotics are likely to colonize, proliferate 
and produce their metabolites.51,69,73,74 
Lactobacillus rhamnosus GG is one of the best stu-
died probiotic strains and plays a role in the pre-
vention or treatment of antibiotic-associated 
diarrhea, flatulence, rotavirus gastro-enteritis, and 
stomach and abdominal pain.26,27,71,72 However, 
when L. rhamnosus GG in fermented milk was 
administered to human volunteers, the strain 
showed only limited persistence in feces and could 
not be recovered in 67% of the subjects after 7 days 
of the last dosage.75 The same results were obtained 
when a milk formula containing the strain was fed 
to premature infants.76 However, Alander et al.74 
did recover L. rhamnosus GG from colonic biopsies 
for lengthy periods after administration ceased. 
Human volunteers were administered with 
6 × 1010 CFU of L. rhamnosus GG twice a day for 
12 consecutive days. Cell numbers of L. rhamnosus 
GG in the feces decreased with time after the last 
bacterial dosage was administered. No cells of 
strain GG were detected in feces 14 days after the 
last dosage. However, L. rhamnosus GG persisted in 
biopsies taken from the colonic mucosa for up to 
21 days at 7 × 104 CFU/biopsy sample after con-
sumption ceased.74 Concluded from these studies, 
Figure 1. Probiotic mechanisms of action against enteric pathogens in the GIT. Probiotics can affect epithelial barrier integrity by 
numerous mechanisms. These include: A. direct effects on the intestinal epithelial cells (IECs). Probiotics can increase the secretion of 
mucin glycoproteins by goblet cells that assemble into a thick mucus layer. Probiotics can augment the secretion of antimicrobial 
proteins (defensins) by IECs that help to eliminate commensals or pathogens that penetrate the mucus layer. Probiotics can enhance 
the stability of intercellular junctional complexes (tight junctions (TJ)), which decreases the intercellular permeability of IECs to 
pathogens and other antigens. B. Most probiotics can inhibit enteric pathogens via the production of antimicrobial substances such as 
bacteriocins. C. Probiotics can compete with commensals and enteric pathogens for adhesion sites in the mucus layer or IECs, thereby 
preventing harmful colonization and enhancing barrier function. Probiotics can alter the natural gut microbiota composition and/or 
gene expression, enhancing barrier integrity through the commensal microbiota. Figure created in biorender (http://biorender.io).
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fecal cell counts are not a true reflection of the 
number of viable cells in the GIT of humans and 
should be accompanied with intestinal biopsies at 
sites of colonization.
Competitive exclusion of enteric pathogens
The term competitive exclusion was first used by 
Greenberg (1969) to describe the exclusion of 
S. typhimurium from blowfly maggots.77 This anti- 
pathogenic mechanism describes the scenario in 
which one bacterial species rigorously competes 
for adhesion to receptors in the GIT. The mechan-
isms of action used by one bacterial species to 
exclude another from the GIT differ and may 
include microbe-microbe interactions mediated by 
binding to the host mucosal interface at specific 
attachment sites, the secretion of antimicrobial sub-
stances and competition for available 
nutrients.14,15,17,18
For enteropathogens to initiate infection, they 
have to cross the intestinal mucosal barrier before 
colonizing the GIT.78 Once pathogens have pene-
trated the mucus layer overlying the intestinal 
epithelium, they attach to binding sites on epithelial 
cells.79 Attachment is followed by intestinal coloni-
zation and infection.80 Probiotics with adhesion 
capabilities protect the gut against enteric infec-
tions by preventing the attachment of pathogens 
Figure 1. Results from in vitro studies using human 
or animal mucosal material have demonstrated the 
effect of probiotic LAB on the competitive exclu-
sion of pathogens.25,48,81–83 Lactobacillus 
rhamnosus GG has excellent adhesion properties 
and prevented the internalization of enterohemor-
rhagic E. coli (EHEC) in human intestinal cell 
lines.81 Enteric pathogens, such as EHEC, use man-
nose-sensitive type 1 fimbriae to attach to oligosac-
charide residues of glycoproteins or glycolipids on 
the surface of intestinal epithelial cells (IECs).84 
Probiotic strains of lactobacilli and bifidobacteria 
attach to the same receptor sites and exclude patho-
gens from binding to the GIT.85,86 Some probiotic 
strains have specific adhesion proteins on their cell 
surface that bind to carbohydrate moieties in the 
mucous layer, such as the mannose-specific adher-
ence mechanism of L. plantarum.13,87,88 In some 
cases, competitive exclusion may be as simple as 
steric hindrance.88 An overview of studies that 
analyzed the effect of probiotic LAB surface pro-
teins on adhesion and competitive exclusion using 
mutant analysis is provided in Table 3. One exam-
ple of a specific adhesion protein involved in com-
petitive exclusion adhesion-receptor interactions in 
the GIT is the L. plantarum mannose-specific adhe-
sion (Msa) protein.87 A spontaneously mutated 
strain of the probiotic L. plantarum 299 v, thought 
to be affected in the msa gene, was unable to inhibit 
the attachment of EHEC to HT-29 epithelial cells 
compared to the wild-type.91 This suggested that 
Msa-containing probiotic strains could effectively 
exclude several other, if not all, type 1 fimbriated 
enteropathogens. Recently, Van Zyl et al.37 demon-
strated the involvement of the mucus-adhesion 
protein (mapA) of L. plantarum 423 in competitive 
exclusion of Listeria monocytogenes EGDe in vivo, 
Table 3. Predicted function and mutant phenotypes of probiotic LAB cell surface adhesion genes.
Strain Gene Predicted function Mutant phenotype
L. plantarum WCFS1 
89
srtA Sortase Reduced mannose-specific binding; competitive ability in murine GIT not 
affected
L. plantarum WCFS1 
89
msa Mannose-specific adhesin Reduced mannose-specific binding
L. plantarum WCFS1 
90
lp_2940 Sortase-dependent cell wall protein Reduced persistence in murine GIT
L. plantarum 299 v 91 msa Mannose-specific adhesin Reduced capability to prevent adherence of EHEC to HT-29 cells
L. plantarum 423 37 mapA Mucus – adhesion protein (MapA) Reduced capability to exclude Listeria monocytogenes EGDe from the GIT of mice
L. acidophilus NCFM 92 mub Mucus-binding protein (MUB) Reduced binding to human Caco-2 cells
L. acidophilus NCFM 92 slpA S-layer protein Reduced binding to human Caco-2 cells
L. salivarus UCC18 93 srtA Sortase Reduced binding to human Caco-2 and HT-29 cells
L. salivarus UCC18 93 lspA Large surface protein (LSP), putative 
MUB
Reduced binding to human Caco-2 and HT-29 cells
L. salivarus UCC18 93 lspB LSP, putative MUB Binding to human Caco-2 and HT-29 cells not affected
L. reuteri 100–23 94 lsp LSP Reduced persistence in murine GIT
L. johnsonii NCC533 21 LJ1476 Transpeptidase Sortase Colonization dynamics similar to that of wild-type
E. mundtii ST4SA 37 srtA Sortase-dependent cell wall protein Reduced capability to exclude L. monocytogenes EGDe from the GIT of mice
E. mundtii ST4SA 37 srtC Sortase-dependent cell wall protein Reduced capability to exclude L. monocytogenes EGDe from the GIT of mice
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using gene knockout analysis and BLI. The mapA 
negative mutant strain of L. plantarum 423 was 
unable to exclude L. monocytogenes EGDe.37
Another example of a putative competitive 
exclusion factor is the collagen-binding protein of 
L. fermentum. Heinemann et al.95 characterized the 
collagen surface-binding protein of L. fermentum 
RC-14, which inhibited the adherence of E. faecalis 
1131. Other studies have demonstrated the role of 
surface layer (S-layer) extracts in the prevention of 
pathogens from attaching to, and thus colonizing, 
IECs.96,97 Chen et al.96 showed that S-layer proteins 
anchored on the cell surface of Lactobacillus crispa-
tus ZJ001 were responsible for competitive exclu-
sion of S. typhimurium and EHEC. Similar results 
were recorded by Johnson-Henry et al.97 The 
authors showed that S-layer protein extracts from 
Lactobacillus helveticus R0052 inhibited the adhe-
sion of E. coli O157:H7 to Caco-2 cells. S-layer 
proteins are highly hydrophobic and it was sug-
gested that pathogen adherence inhibition was 
mediated by hydrophobic group interactions as 
opposed to adhesion-receptor interactions.
Previous studies suggested that sortase- 
dependent cell surface proteins (SDPs) play 
a crucial role in probiotic-host interactions, adher-
ence and colonization.98–102 Several SDPs have 
been identified with a role in in vitro and in vivo 
adhesion to intestinal cells, including mucus- 
binding cell surface proteins Table 3. In Gram- 
positive bacteria, sortases decorate the cell surface 
with a diverse array of proteins by covalently join-
ing them to the cell wall (Sortase A) or by polymer-
izing proteins to construct complex multi-subunit 
pilin structures (Sortase C) on the cell surface.99 
Sortases are characterized as cysteine transpepti-
dases that join SDPs containing a specific cell wall 
sorting signal (CWSS) to an amino group located 
on the cell surface.100 Sortase A enzymes anchor 
proteins that contain a CWSS with a LPXTG 
(where X donates any amino acid) C-terminal 
motif to the cell surface.99 The LPXTG motif is 
recognized by the SrtA enzyme, which breaks the 
threonine and glycine peptide bond and then cova-
lently links the threonine residue to the amino 
group of the pentaglycine bacterial cell wall cross 
bridge.93,101 Sortase C proteins catalyze a similar 
transpeptidation reaction, but recognize 
a QVPTGV sorting motif to construct pili that 
promote microbial adhesion.102 Using mutant ana-
lysis coupled with in vivo BLI, a recent study 
showed that E. mundtii ST4SA sortase mutants 
(srtA and srtC) had a reduced ability to exclude 
L. monocytogenes EGDe from the GIT of mice 
compared to the wild-type derivative.37
Several strains of lactobacilli and bifidobacteria 
inhibit, displace, and adhere to the same enterocyte 
layer as, enteropathogenic Salmonella choleraesuis 
serovar Typhimurium .103 This indicates that the 
probiotic strains have the ability to effectively dis-
place the pathogen after pathogenic colonization of 
the gut has occurred instead of being effective only 
when administered in a preventative manner. To 
gain a competitive advantage, the probiotics can 
thus modify the gut environment by producing 
inhibitory compounds, lowering pH levels and 
competing for nutrients.64 Lactobacillus species 
such as L. acidophilus and L. plantarum have the 
ability to utilize complex carbohydrates such as 
fructans.104,105 Similarly, bifidobacteria are capable 
of metabolizing various plant dietary fibers using 
several depolymerizing enzymes.105 Utilizing car-
bohydrate sources other than those used by enter-
opathogenic bacteria enable probiotic bacteria to 
widen their areas of colonization in the GIT and 
inhibit pathogens.
Production of antimicrobial compounds
Antimicrobial compounds, produced by probiotic 
bacteria, can exert direct antimicrobial action 
toward competing enteropathogens that may lead 
to the prevention of pathogenic colonization of the 
GIT Figure 1b.
Bacteriocins
Bacteriocins are ribosomally produced antimicro-
bial peptides that differ in terms of their size (2–10 
kDa) and mechanisms of action (for a review, see 
ref. 108). The production of bacteriocins by pro-
biotic bacteria (usually LAB) is a key mechanism of 
action used to inhibit pathogens in the GIT. 
Bacteriocins usually only inhibit specific species, 
often those closely related to the producer.106,107 
Some bacteriocins are reported to have a much 
broader spectrum of antimicrobial activity.107–111 
Bacteriocins such as nisin, produced by Lc. lactis, 
e1831339-6 W. F. VAN ZYL ET AL.
plantaricin from L. plantarum and lacticin B from 
L. acidophilus are active against food-borne enter-
opathogens such as Listeria, Clostridium, Bacillus, 
methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci (VRE).14–119 
Bacteriocins may have a bacteriostatic or direct 
bactericidal effect on pathogens, thus limiting the 
ability of the cells to colonize the gut. The asso-
ciated antimicrobial activities of bacteriocins allow 
bacteriocin-producing probiotic strains to gain 
a competitive advantage within the complex GI 
environment.120
Bacteriocins adhere to microbial cells and penetrate 
phospholipid membranes due to their small size and 
variations in hydrophobic and hydrophilic 
properties.121 The general mechanisms of bacteriocin- 
mediated pathogen killing include the induction of 
cytoplasmic membrane permeabilization of sensitive 
bacteria that leads to cell leakages, inhibition of DNA 
and RNA synthesis and/or cell wall protein- 
synthesis.117,122,123 For instance, nisin acts by forming 
a complex with the cell membrane lipid II precursor, 
followed by the aggregation and incorporation of 
peptides to form discrete pores in the bacterial cell 
membrane.124 A unique bacteriocin, bifidocin B, pro-
duced by Bifidobacterium bifidum NCFB, is active 
against several Gram-positive bacteria, including 
Listeria, Enterococcus, Bacillus and Lactobacillus, but 
shows no activity toward several other Gram-positive 
and Gram-negative bacteria.125 The difference in 
activity between strains is related to the ability of 
Gram-negative bacteria to resist adsorption of bifido-
cin B, due to their cell wall composition.126 However, 
several bacteriocins, such as mutacins (A-D), nisins 
(A and Z), lacticins (A164 and BH5), bacteriocins 
E 50–52 and OR7 are active against medically impor-
tant Gram-negative organisms such as 
Campylobacter, Helicobacter, Haemophilus, Neisseria 
and Salmonella spp.127–132 In another study, 
a bacteriocin produced by Bacillus amyloliquefaciens 
RX7 showed broad-spectrum antibacterial, as well as 
antifungal, activity and inhibited the growth of 
Candida albicans, the causative agent of cutaneous 
candidiasis in humans.133 While the mode of action 
of bacteriocins against Gram-positive bacteria has 
been studied in depth, the direct mechanism of action 
of bacteriocins against Gram-negative bacteria is 
poorly understood.132,134 Tiwari et al.134 demon-
strated the ability of bacteriocins enterocin E50-52, 
pediocin PA-1 and its hybrid peptides, EP and PE, to 
induce the efflux of intracellular ATP and to dissipate 
the cellular transmembrane potential of E. coli O157: 
H7 and S. enterica serovar Enteritidis 20E1090. 
Bacteriocins are mostly cationic peptides, and this 
characteristic enables electrostatic interactions with 
the negatively charged head groups of bacterial 
phospholipid.135 This is followed by insertion into 
the planar lipid bilayer or liposome membranes, lead-
ing to the formation of transient channels, leakage of 
cellular contents and subsequent cell death.136
In addition to in vitro studies, several in vivo 
studies have demonstrated the inhibitory effect of 
purified bacteriocins and probiotic bacteriocin- 
producing strains in infectious animal models. 
Simonova et al.137 observed that feeding rabbits 
with bacteriocin-producing Enterococcus faecium 
CCM7420 and its partially purified bacteriocin sig-
nificantly reduced Staphylococci spp. cell numbers 
in the cecum thus protecting the animals against 
infection. Other studies found that the E. faecium 
EK13, enterocin A producing strain reduced 
Salmonella cell numbers in gnotobiotic Japanese 
quails and reduced the colonization of pathogenic 
Staphylococcus in the digestive tract of 
rabbits.138,139 The capacity of human-isolated 
nisin- and pediocin-producing LAB to reduce the 
intestinal colonization of VRE in mice was demon-
strated for the first time by Millette et al.38 
Amyloliquecidin and penisin, produced by 
B. amyloliquefaciens and Paenibacillus sp. strain 
A3, respectively, significantly reduced methicillin 
resistant S. aureus (MRSA) infection levels in 
mice.140,141 Svetoch et al.142 reported a significant 
reduction of Salmonella enteritidis in broilers after 
oral administration of the E. faecium E 50–52 bac-
teriocin. Corr et al.35 demonstrated that feeding 
mice with the Lactobacillus salivarus UCC11 bac-
teriocin Abp118-producing strain reduced 
L. monocytogenes cell numbers in the liver and 
spleen. A similar reduction in cell numbers of the 
same pathogen in the GIT of mice was observed 
when the animals were pre-treated with probiotic 
strains L. plantarum 423 and E. mundtii ST4SA, 
producing bacteriocins plantaricin 423 and mund-
ticin ST, respectively.36 Using gene knockout and 
reverse genetic analysis, the same authors con-
firmed bacteriocin production and adhesion pro-
teins as mechanisms for the anti-listerial activity.37
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Several studies have demonstrated the topical 
application of bacteriocins to treat skin infections, 
mastitis and oral infections.140–147 Despite their 
powerful anti-infective therapeutic potential and 
a large selection of isolated and characterized bacter-
iocins, these peptides have not yet entered into clin-
ical use.148–150 This is likely due to various 
production difficulties.149,151 However, progress in 
preclinical studies of several bacteriocins has proven 
promising. Several bacteriocins have been through 
different stages of preclinical development, targeting 
multi-drug resistant bacteria as well as cystic 
fibrosis.149 These include the bacteriocins, NVB302 
and NVB333 (both produced by Actinoplanes liqur-
iae NCIMB41362), mutacin 1140 (produced by 
Steptococcus mutans JH1000), NAI-107 (produced 
by Microbispora corallina) and Moli1901 (produced 
by Streptomyces cinnamoneum).149
It is also important to consider that not all poten-
tial or developed probiotic strains that show in vitro 
antimicrobial activity against enteropathogens will 
be active in vivo. For example, despite the fact that 
a Lactobacillus sp. strain adhered to the jejunum and 
ileum of gnotobiotic pigs after oral administration 
and that the strain showed in vitro activity against 
enteropathogenic E. coli (EPEC), the strain failed to 
prevent EPEC colonization in the GIT of infected 
animals.152 Similar results were observed when 
L. casei subsp. casei failed to prevent the intestinal 
colonization of EPEC in the GIT of gnotobiotic or 
conventional piglets when the LAB strain was admi-
nistered in a preventative setup.153 Nevertheless, 
most probiotics use their bacteriocins to effectively 
interact with enteropathogens through either bacter-
iostatic or bactericidal activities. In doing so, they 
prevent pathogenic colonization of the host GIT and 
subsequent occurrence of disease.
Bacteriocin-like inhibitory substances
Bacteriocin-like inhibitory substances (BLIS) have 
a broader spectrum of antimicrobial activity. Many 
of these compounds are not fully characterized or do 
not share characteristics typical of bacteriocins.12 The 
antimicrobial activities are not related to the produc-
tion of lactic acid, other organic acids, or hydrogen 
peroxide.12,154 Lactobacillus rhamnosus GG secretes 
an antimicrobial substance with inhibitory activity 
against Clostridium spp., Staphylococcus spp., 
Enterobacteriaceae, Streptococcus spp., Bacteriodes 
spp., and Pseudomonas spp.155 This low molecular 
weight (LMW) substance is characterized as heat- 
stable, distinct from lactic and acetic acids, and closely 
resembles a microcin that is normally produced by 
Enterobacteriaeae spp. These characteristics suggest 
that it could be a BLIS.12 Similar substances with 
molecular weights and broad activity spectrums 
uncharacteristic of bacteriocins are produced by 
other lactobacilli, including strains of L. acidophilus 
and L. delbrueckii, their bactericidal affects are related 
to neither lactic acid nor hydrogen peroxide.156,157 
Other studies have identified bacteriocin-like antimi-
crobial substances produced by several 
Bifidobacterium strains with broad spectrums of activ-
ity against both Gram-positive and Gram-negative 
pathogens such as L. monocytogenes, Salmonella spp. 
and E. coli spp.158–160
Organic acids
An additional mechanism of pathogen displacement 
in the gut employed by probiotic bacteria is their 
ability to make the intestinal environment less sui-
table for pathogen growth. Probiotic LAB and com-
mensal microbiota ferment carbohydrates in the GIT 
that lead to the production of metabolites such as 
acetic, formic, succinic and lactic acids, rendering 
the intestinal environment acidic and inhibiting the 
growth of bacterial pathogens.161 Organic acids, in 
particular lactic and acetic acid, repress the growth of 
many pathogenic bacteria in the GIT.12,15,64 The 
undissociated form of lactic acid functions as 
a permeabilizer of the Gram-negative bacterial 
outer cell membrane, after which it dissociates inside 
the bacterial cytoplasm following entry.162 The bac-
terial killing activity is exerted by lowering the intra-
cellular pH level, through the accumulation of 
ionized forms of the organic acid and other antimi-
crobial compounds inside the cytoplasm.163
De Keersmaecker et al.164 demonstrated that the 
strong inhibitory effects of L. rhamnosus GG 
against S. typhimurium was due to lactic acid pro-
duction. Lehto and Salminen165 demonstrated the 
potential role of lactic acid in the ability of 
Lactobacillus strain GG to prevent the invasion of 
Caco-2 cells by S. enterica serovar Typhimurium. 
The authors suggested a pH-dependent mechanism 
after they observed that inhibition of the pathogen 
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was eliminated when the LAB culture was set to pH 
7. In another study, the growth and expression of 
the HilA and InvF virulence factors by Salmonella 
were affected by lactic acid.166
The inhibition of E. coli O157:H7 by different 
Lactococcus and Lactobacillus strains was attributed 
to the production of lactic acid and low pH.167,168 The 
growth of Helicobacter pylori was inhibited by differ-
ent Lactobacillus and Bifidobacterium strains includ-
ing L. acidophilus, L. bulgaricus and Bifidobacterium 
bifidus.169,170 These effects were linked to the 
production of lactic, acetic and hydrochloric acid. In 
another study, the growth of four species of known 
enteropathogens, H. pylori, Campylobacter jejuni, 
Campylobacter coli and C. difficile was inhibited by 
Lactobacillus strains isolated from the human GIT, 
probably due to the production of organic acids.171 
Based on these studies, it is reasonable to suggest that 
the production of organic acids by probiotics in the 
GIT makes the intestinal environment less favorable 
for their competitors and decreases the risk of enteric 
infections by pathogens.
Figure 2. Mucosal immunomodulation by probiotics in the presence of enteric pathogens. A. Down-regulation by probiotic bacteria of 
pro-inflammatory cytokine (IL-8) secretion in the GIT. Probiotic bacteria (or their products) may dampen an innate immune response by 
inhibiting the NF-ƘB inflammatory signaling pathway and influencing the production of IL-8 and subsequent recruitment of 
inflammatory immune cells to sites of intestinal injury. B. Activation of NF-ƘB signaling pathway by enteric pathogens, resulting in 
severe inflammation of intestinal epithelium tissue. C. Probiotic signaling of dendritic cells (DCs) to stimulate the secretion of anti- 
inflammatory cytokines such as IL-10 in response to an intestinal infection. D. Probiotics can augment the levels of IgA-secreting 
plasma cells in the lamina propria and promote the transcytosis of secretory IgA (sIgA) across the epithelial cell layer and secretion into 
the luminal mucus layer, preventing and limiting bacterial penetration of host tissues. IECs, intestinal epithelial cells; IL-8, interleukin 8; 
IL-10, interleukin 10; MФ, macrophage; NФ, neutrophil; NF-ƘB, nuclear factor-kappa B. TGFβ, transforming growth factor-β; Th1-3, 
T helper cells; Treg, regulatory T cells. Figure created in biorender (http://biorender.io).
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Hydrogen peroxide
In addition to lactic acid and bacteriocin produc-
tion, hydrogen peroxide (H2O2) production by 
commensal or probiotic LAB may be an important 
antimicrobial mechanism against pathogens.172 
Hydrogen peroxide may cause reduced pathogen 
virulence, reduced pathogen invasion of epithelial 
cells or death of intestinal pathogens after epithelial 
intracellular diffusion which alters gene transcrip-
tion and signal transduction.173,174 Several H2O2- 
producing bacterial species with probiotic proper-
ties have been isolated, such as B. bifidum, the 
Lactobacillus johnsonii NCC 533 gut isolate, 
a L. delbrueckii subsp. bulgaricus yogurt isolate 
and normal microflora vaginal isolates such as 
L. crispatus and L. gasseri.174–181
The ability of L. johnsonii NCC533 to generate 
up to millimolar quantities of H2O2 under aerobic 
conditions has been demonstrated.176 The authors 
demonstrated the antimicrobial role of L. johnsonii 
NCC533 produced H2O2 against S. enterica serovar 
Typhimurium in vitro, and proposed that 
L. johnsonii NCC533 H2O2-production could con-
tribute to protection against the pathogen in vivo. 
Other studies have shown that H2O2-producing 
L. crispatus F117 and Lactobacillus paracasei strains 
(F2 and F28) inhibited the growth of S. aureus in -
vitro.181,182 The beneficial role of H2O2-producing 
probiotic LAB that form part of the vaginal micro-
flora of healthy women has been studied 
extensively.180–183 Previous studies have reported 
that women carrying H2O2-producing lactobacilli 
are less likely to develop bacterial vaginosis.180,183
Siderophores
Iron is an essential micronutrient that plays a central 
role in the metabolism and proliferation of most gut 
microbes, including commensal bacteria and gut 
pathogens.184 Siderophores are LMW, organic, high- 
affinity iron-chelating compounds produced by 
microorganisms such as bacteria and fungi.185 
These compounds inhibit the growth, proliferation 
and persistence of competing microbes by depriving 
them of iron. In doing so, siderophore-producing 
bacteria sequester free iron available in their envir-
onment that is essential to other microorganisms. 
For example, the growth of Lc. lactis, C. difficile 
and Clostridium perfringens was inhibited in the 
GIT by iron-binding Bifidobacterium strains that 
produce siderophores.186 Growth and adhesion of 
enteropathogenic S. typhimurium N15 and EHEC 
to IECs were inhibited by B. pseudolongum PV8-2 
and Bifidobacterium kashiwanohense PV20-2 with 
high iron sequestration properties.187
Biosurfactants
The production of biosurfactants by some LAB is 
another mechanism that can interfere with patho-
gen growth in the GIT. Biosurfactants are a group 
of compounds with surface and emulsifying activ-
ities used in many different biomedical 
applications.188,189 Several LAB strains have been 
isolated that produce either cell-bound or secreted 
biosurfactants with antibacterial, antiviral and anti-
fungal properties.188–193 Biosurfactants cause per-
meabilization of cells by effecting changes that 
disrupt or lyse the physical cell membrane 
structure.194 The use of biosurfactant-producing 
lactobacilli in the prevention of urogenital tract 
infections is of considerable interest.188 These 
organisms are believed to compete with urogenital 
bacterial pathogens and yeast for adhesion sites on 
epithelial cells and control their growth by the 
production of biosurfactants.195–197 In another 
study, L. casei MRTL3 that produces a bacteriocin 
and a biosurfactant, inhibited a broad range of 
pathogens, including L. monocytogenes, S. aureus, 
Shigella flexneri and Pseudomonas aeruginosa.198
Compounds inhibiting pathogen adhesion to 
intestinal cells
Adhesion to intestinal cells and subsequent coloni-
zation by enteropathogens is regarded a prerequisite 
for virulence.199 Probiotic bacteria produce com-
pounds that do not have a direct bactericidal effect, 
but contribute to the normal anti-infectious activities 
of the GIT by inhibiting the binding of pathogenic 
bacteria to the mucosal surface. Fujiwara et al.200 
purified and characterized a novel proteinaceous 
compound in culture supernatants of B. longum 
SBT2928, termed BIF, that inhibits the adhesion of 
enterotoxigenic E. coli Pb176 (ETEC) to human 
HCT-8 IECs. The authors demonstrated that BIF 
blocks the binding of the ETEC Pb176 colonization 
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factor antigen (CFA) II adhesive factor to gangliote-
traosylceramide (bacterial binding structure) recep-
tors on the intestinal cell surface, thereby preventing 
ETEC Pb176 colonization.200 Two Bifidobacterium 
strains, CA1 and F9, isolated from the GIT of infants 
produce a LMW, lipophilic, antibacterial compound 
that inhibits the adhesion of several pathogenic bac-
teria, including S. typhimurium SL1344 and E. coli 
C1845.201
Stabilization of intestinal epithelial barrier
The GI epithelium consists of a uni-layer of cells 
covered by a mucus layer that is constantly exposed 
to the luminal contents and various enteric 
bacteria.78,202 The intestinal epithelial barrier con-
sists of the mucus layer, the intestinal cells and the 
gut innate immune system.202 This GI barrier func-
tions as a key defense mechanism required to main-
tain epithelial integrity and to prevent infection by 
pathogens and excessive inflammation. Stabilization 
and maintenance of this barrier is thus of utmost 
importance to the host. Important defense mechan-
isms of the intestinal barrier against unwelcome 
intrusion of harmful antigens include the mucosal 
layer (mucin production), intercellular junctional 
complexes (tight and adherence junctions) and the 
secretion of antimicrobial peptides (such as defen-
sins) and immunoglobulin A (IgA).202–205 
Disruption of this barrier function can lead to inap-
propriate inflammatory responses due to invasion of 
the submucosa by bacteria or food antigens, which 
may result in intestinal disorders such as inflamma-
tory bowel disease (IBD) and ulcerative 
colitis.203,206,207 Consumption of colonizing or non- 
colonizing probiotics can enhance barrier integrity 
which helps to protect the intestinal epithelium 
against enteric pathogens and chronic inflammation 
by direct effects on the epithelium (e.g. increasing 
mucin expression by goblet cells), modulation of the 
immune system and by direct effects on commensal 
and pathogenic bacteria (e.g. antimicrobial peptides 
and competition for adherence) Figures 1 and 2.
Intestinal epithelium cells are overlaid with 
a protective inner and outer mucus layer that limits 
bacterial movement and acts as a dynamic defense 
barrier against enteropathogens and other poten-
tially harmful antigens.204 For enteropathogens to 
colonize the intestine, they have to penetrate the 
mucus layer before they reach the intestinal 
epithelium.208 Mucins are the major macromolecu-
lar constituents of the epithelial mucus layer and are 
produced by specialized goblet cells in the intestinal 
tract.209 Probiotics are able to inhibit pathogen 
adherence to IECs by promoting the secretion of 
intestinal mucins and defensins Figure 1a. Several 
Lactobacillus species have been shown to increase the 
expression of specific mucin genes in human intest-
inal Caco-2 and HT29 cells, thus preventing the 
adherence and internalization of pathogenic 
E. coli.91,210,211 The adherence of EPEC was inhibited 
by L. plantarum 299 v-mediated increase in expres-
sion of the MUC2 and MUC3 mucins.91,211 Rats 
administered with VSL3 (pre- and probiotic mix-
ture) for 7 consecutive days showed a 60-fold 
increase in MUC2 expression and an associated 
increase in mucin production.212 Therefore, 
increased mucus production mediated by probiotic 
bacteria in vivo may be a key mechanism in their 
interactions with enteropathogens to prevent infec-
tions and to improve intestinal barrier function.
Co-aggregation
Probiotic bacteria can prevent enteropathogenic 
adherence and intestinal colonization by co- 
aggregating with pathogens.213–215 In this process, 
probiotic bacteria interact closely with pathogens, 
allowing them the opportunity to release their anti- 
pathogenic substances in proximity to the pathogens. 
Probiotic LAB can form multi-cellular aggregates that 
are crucial for colonization of the oral cavity, the 
urogenital tract and the GIT.37,213,215–217 The ability 
of probiotic cells to co-aggregate is characterized by 
the clumping of cells that are genetically distinct, 
whereas auto-aggregation involves cells of the same 
strain.218,219 Auto- and co-aggregation have been 
reported for various Lactobacillus species, including 
L. plantarum, L. reuteri, L. gasseri, L. crispatus and 
L. coryniformis.219,220 Several studies have shown that 
the auto- and co-aggregation abilities of probiotic cells 
enhances their colonization and may enable the for-
mation of a barrier to prevent colonization by 
pathogens.213–215,218 Lactobacillus plantarum strains 
(S1, A and B) co-aggregate with selected food-borne 
pathogens including S. typhimurium and 
L. monocytogenes.218 Lactobacillus plantarum S1 co- 
aggregated best with EHEC at 41.5%, L. plantarum 
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A co-aggregated with S. Typhimurium at 40.5% and 
L. plantarum B co-aggregated with L. monocytogenes 
at 37.4%.218 This is a clear indication that the ability of 
LAB strains to bind to the food-borne pathogens is 
not restricted to one species or a single strain. In 
another study, the adherence of ETEC to porcine 
enterocytes was affected by co-aggregation of the 
pathogen with selected Lactobacillus spp., including 
L. fermentum, L. salivarius and L. delbrueckii. 221
The co-aggregation ability of probiotic LAB is 
generally related to a great diversity of properties 
among cell surface adherence proteins.222,223 Kos 
et al.215 demonstrated that differences in the hydro-
phobicity and hydrophilicity of the structural cell 
surface of L. acidophilus M9, L. plantarum L4 and 
E. faecium L3 may be responsible for the abilities of 
the strain to co-aggregate. In other examples, pro-
teins involved in the maintenance of cell shape 
including the S-layer protein CbsA of L. crispatus 
JCM 5810, the DEAD box helicase AggH of L. reuteri 
1063 and Apf of L. gasseri 4B2 were all responsible 
for the mediation of auto-aggregation.224–226 This 
suggests that the co-aggregation phenomenon of 
probiotic LAB may be a secondary activity of cell 
surface components involving random interactions 
with other surface components. Schachtsiek et al.219 
described the role of a Lactobacillus coryniformis 
DSM 20001 surface protein encoded by a cpf gene 
(co/aggregation-promoting factor) in the ability of 
the LAB strain to co-aggregate with E. coli K-88, 
C. coli and C. jejuni. The auto- and co-aggregation 
ability of L. acidophilus M92 was shown to be 
mediated by proteinaceous surface layer (S-layer) 
components, approximated at 45 kDA in size.215
Co-aggregation of probiotic and pathogenic bac-
teria is also mediated via the attachment of probio-
tic cells to fimbriae expressed on the cell surface of 
pathogens.213 This makes sense, as several studies 
have shown that probiotic LAB can prevent enter-
opathogenic binding to intestinal epithelial cells by 
attaching to the same carbohydrate receptor sites as 
the pathogens.14,18,85,86 The attachment of probio-
tic cells to the surface of pathogenic cells is depen-
dent on the specific type of fimbriae expressed by 
the pathogen.213 The expression of fimbriae by 
pathogens is important in colonization of the GIT, 
the vagina and perineum.84,196,213,227 For example, 
E. coli that express type I fimbriae are most com-
monly associated with urinary tract infections.227 
Mizuno et al.220 presented E.coli fimbriae and lipo-
polysaccharide (LPS) as the essential mediators of 
the co-aggregation of L. casei NBRC 3831 with 
E. coli K-12. Spencer and Chesson221 showed that 
selected strains of lactobacilli co-aggregate with 
enterotoxigenic E. coli expressing K88 fimbriae, 
but not with a K88-negative knockout mutant 
strain.
Inhibition of flagella motility
Flagella are known to play an important role as 
a virulence factor in many bacterial pathogens.228 
Flagella allow pathogenic bacteria to respond to 
attractant and repellent gradients and are crucial 
for attachment to, and invasion of, eukaryotic 
cells.229–232 Foodborne pathogens such as 
S. enterica serovar Typhimurium require actively 
rotating flagella to rapidly contact and to efficiently 
penetrate GI epithelial cells. Salmonella 
Typhimurium remained noninvasive in infected 
mice when treated with a potent antibody that 
inhibits flagellum-based motility.233 Probiotic bac-
teria can impair the flagella motility of entero-
pathogens, thus preventing pathogenic 
colonization of the gut.
Líeven-Le Moal et al.234 demonstrated that anti-
diarrhoeic L. acidophilus LB and its secreted pro-
ducts inhibited the entry of S. enterica serovar 
Typhimurium into human intestinal Caco-2 cells 
by disrupting the swimming motility of the diar-
rhea-associated enteropathogen. The authors 
showed that L. acidophilus LB secretes a heat stable 
LMW product that causes rapid depolarization of 
the S. Typhimurium SL1344 cytoplasmic mem-
brane. The inhibitory activity did not affect bacter-
ial viability or flagellum expression. The transient 
impairment of the swimming motility of S. 
Typhimurium SL1344 leads to a delay in the patho-
gen’s capacity to induce F-actin membrane remo-
deling and thus entry into intestinal Caco-2 cells. In 
another study, levels of translocated Salmonella 
were dramatically lower in mice orally infected 
with S. Typhimurium when treated with the cell 
free supernatant of live probiotic lactobacilli, com-
pared to that of untreated mice.235 It is possible that 
the difference between cell numbers of treated and 
untreated groups is due to a delay in pathogen 
translocation across the intestinal epithelial barrier 
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caused by the inhibition of Salmonella swimming 
motility. This in turn, exposed the pathogenic cells 
for extended periods to host defenses in the intest-
inal lumen that includes antimicrobial products 
from both the host cells and the microbiota.
Immune system modulation
It is well known that probiotic bacteria can exert 
regulatory effects on host innate and adaptive 
immune responses.236 These bacteria have the ability 
to modulate the functions of dendritic cells (DCs), 
monocytes/macrophages, and T and B lymphocytes, 
which enhances phagocytosis of invading gut 
pathogens.237,238 By stimulation of the host immune 
responses (specific and nonspecific), probiotic bac-
teria can displace pathogens in the GIT and prevent 
intestinal diseases.238–241
Probiotic bacteria can interact with pathogens in 
the gut by antagonizing inflammatory responses 
induced by the gut pathogens.236 Inflammation allows 
pathogens to flourish at the expense of the natural 
microbiota and host intestinal health. Probiotic bac-
teria are able to trigger an anti-inflammatory response 
from the innate immune system by signaling DCs to 
secrete anti-inflammatory cytokines such as interleu-
kin 10 (IL-10) Figure 2c.242,243 They can also elicit 
a decrease in pro-inflammatory cytokines during 
inflammation.237 Down-regulation of pro- 
inflammatory cytokine secretion from immune cells 
occurs as a result of probiotic bacterial interference 
with inflammatory signaling pathways such as nuclear 
factor-kappa B (NF-ƘB) and mitogen-activated pro-
tein kinases (MAPK) Figure 2a.244,245 The activation 
of these signaling pathways leads to the secretion 
of pro-inflammatory cytokines that can severely 
damage the intestinal epithelial barrier. NF-Ƙ 
B and MAPK signaling pathways are activated 
by enteric pathogens to stimulate the secretion 
of pro-inflammatory cytokines (e.g. IL-8), that 
lead to the recruitment of inflammatory immune 
cells (e.g. neutrophils) to the infected area result-
ing in severe inflammation, tissue damage and 
disease Figure 2b.244,245 Several studies have 
identified probiotic strains with the ability to 
suppress pro-inflammatory cytokine production 
to avoid pathogen-induced inflammation at 
infection sites.236,245–247 A study by Finamore 
et al.246 reported that Lactobacillus amylovorus 
DSM 16698 protected IECs against the pro- 
inflammatory response induced by ETEC K88 
through the suppression of pro-inflammatory 
cytokines IL-8 and IL-1ß. Another study demon-
strated the ability of L. casei OLL2768 to sup-
press the ETEC-induced pro-inflammatory 
response by inhibition of NF-ƘB and MAPK 
pathways that reduced pro-inflammatory cyto-
kine levels.247
Probiotics also play a role in the stimulation and 
production of antibodies in the gut, particularly 
immunoglobulin A (IgA) Figure 2d.236,237 
Antibodies released in the intestinal lumen can 
inhibit pathogen adherence to IECs by interfering 
with adhesive cell receptors on the pathogen’s cell 
membrane. Previous studies have indicated that 
Saccharomyces boulardii and L. rhamnosus GG 
increased secretory IgA levels or immunoglobulin- 
secreting cell levels in the GIT.248,249 Other studies 
have reported that oral administration of probiotic 
lactobacilli increased IgA levels in children suffer-
ing from diarrhea, thereby shortening the duration 
of symptoms.237,250–252 Several probiotic strains 
can also modulate the host immune mechanisms 
by influencing phagocytosis of enteric pathogens by 
host immune phagocytic cells such as 
macrophages.14,18,64,248,251,253,254 The inhibition of 
enteropathogenic P. aeruginosa and 
L. monocytogenes in mice by a strain of L. casei 
correlates to an increase in abundance of 
macrophages.255 Furthermore, probiotic bacteria 
can affect phagocytotic cell activities not only in 
clinical situations but also in healthy 
subjects.256–258
Conclusion
Elucidating the mechanisms of action of probiotic 
microorganisms is a difficult task given the complex 
nature of the human GI ecosystem. Probiotic 
mechanisms of action employed against enteric 
pathogens are diverse, heterogeneous and may be 
strain specific. This suggests that the mechanism(s) 
of action of one specific probiotic strain against 
a particular disease or pathogen cannot be general-
ized since different strains evoke different 
responses in the host. Thus, the health benefits 
conferred by one strain are not applicable to 
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another strain, even within the same species. 
Understanding the full potential of probiotics 
for therapeutic or prophylactic applications 
against GI diseases requires thorough investiga-
tions of probiotic-host and probiotic-pathogen 
interactions. Enhanced understanding of these 
interactions will enable the identification of 
true probiotics to target specific enteric diseases. 
While a number of recent in vivo studies have 
demonstrated the mechanistic basis behind 
observed probiotic effects at the molecular 
level, greater emphasis is warranted in this area 
of probiotic research. Unraveling the intricacies 
of probiotic-host and probiotic-pathogen inter-
actions will improve the in vitro selection of the 
best probiotics based on key properties such as 
bacteriocin production and adhesion genes. 
Moreover, an efficient probiotic should exhibit 
stimulation of the hosts’ immune system and 
ultimately, must have demonstrable beneficial 
health effects on the host. It is clear that the 
demonstration of key antimicrobial and protec-
tive probiotic mechanisms in vivo will allow for 
industry and consumers to choose scientifically 
validated probiotics for the prevention or treat-
ment of various health problems.
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